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Nucleosome positioning at transcription start sites is known to regulate gene expression by altering DNA
accessibility to transcription factors; however, its role at enhancers is poorly understood. We investigated
nucleosome positioning at the androgen receptor (AR) enhancers of TMPRSS2, KLK2, and KLK3/PSA in
prostate cancer cells. Surprisingly, a population of enhancer modules in androgen-deprived cultures showed
nucleosome-depleted regions (NDRs) in all three loci. Under androgen-deprived conditions, NDRs at the
TMPRSS2 enhancer were maintained by the pioneer AR transcriptional collaborator GATA-2. Androgen
treatment resulted in AR occupancy, an increased number of enhancer modules with NDRs without changes
in footprint width, increased levels of histone H3 acetylation (AcH3), and dimethylation (H3K4me2) at
nucleosomes flanking the NDRs. Our data suggest that, in the absence of ligand, AR enhancers exist in an
equilibrium in which a percentage of modules are occupied by nucleosomes while others display NDRs. We
propose that androgen treatment leads to the disruption of the equilibrium toward a nucleosome-depleted
state, rather than to enhancer de novo “remodeling.” This allows the recruitment of histone modifiers,
chromatin remodelers, and ultimately gene activation. The “receptive” state described here could help explain
AR signaling activation under very low ligand concentrations.
Nucleosomes are the basic units of eukaryotic chromatin,
each one containing 146 bp of DNA wrapped around an
octamer of histone core proteins, which in turn are separated
by linker DNA sequences of variable length (39). Nucleosomes
play a pivotal role in chromatin structure, and their differential
occupancy at promoters (transcription start sites) regulates
gene expression by altering DNA accessibility (39). For in-
stance, a nucleosome-depleted region (NDR) at transcrip-
tional start sites correlates with gene expression, whereas the
positioning of a nucleosome over the transcriptional start site
results in gene repression (23). In contrast, the role of nucleo-
some positioning at other regulatory regions, particularly distal
ones such as enhancers, is less well characterized. Interestingly,
nucleosome turnover was recently shown to be increased at
genes and regulatory elements (9), suggesting that this process
may control nucleosome density and the existence of NDRs.
Enhancers are nondirectional regulatory elements that con-
trol promoter activity at a distance on linear DNA. Several
histone marks, including mono- and dimethylated H3K4
(H3K4me1 and H3K4me2) and acetylated H3K9,14 (AcH3),
have been shown to correlate or be associated with regions that
display enhancer activity, although H3K4me2 and AcH3, along
with the trimethylation version of H3K4 (H3K4me3), are also
located at transcriptional start sites (16, 44). Enhancers gen-
erally contain DNA recognition motifs for transcription factors
which, upon binding, regulate gene expression by looping to
the transcriptional start sites of their target genes.
The androgen receptor (AR) is a ligand-dependent nuclear
receptor that plays a major role in prostate cancer onset and
progression (10). The AR is recruited primarily to enhancers
together with transcriptional collaborators, which include the
transcription factors GATA-2, FOXA1, and OCT1/2 (43).
Once an enhancer-protein complex is formed, it communicates
with gene promoter regions through looping, thereby affecting
transcription over large linear DNA distances (41). Using
ChIP-Seq, we have recently demonstrated that androgen-
treated prostate cancer (LNCaP) cells show the expected
strong AR occupancy at the enhancers of kallikrein 3/prostate-
specific antigen (KLK3/PSA) and KLK2 (3). Interestingly, two
well-positioned nucleosomes containing AcH3 were shown to
flank AR-occupied regions in androgen-treated cells (3). A
similar bimodal pattern of histone modifications relative to
transcription factor binding sites at enhancers has been ob-
served in KCl-stimulated murine neurons for H3K4me1 and
CREB binding protein (25) and in LNCaP cells for H3K4me2
and AR (14). Using H3K4me2 ChIP-Seq data from LNCaP
cells and prediction algorithms, He et al. (14) suggested that
AR binding sites at enhancers are occupied by a well-posi-
tioned nucleosome, which is then destabilized and presumably
removed or shifted by the addition of androgens and AR
occupancy. However, this suggestion was based on data gen-
erated by micrococcal nuclease (MNase) I digestion and chro-
matin immunoprecipitation (ChIP) analysis of modified his-
tone tails; the extent of nucleosome occupancy was unclear.
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To characterize the chromatin architecture in AR-occupied
regions, we used a combination of ChIP-Seq, ChIP-qPCR
(quantitative PCR), and a highly sensitive single-molecule
nucleosome occupancy and methylome sequencing (NOMe-
Seq) assay. Here we show that in androgen-depleted LNCaP
and LAPC4 cells, a percentage of the enhancer modules of the
three well-known AR targets KLK3/PSA, KLK2, and trans-
membrane protease serine 2 (TMPRSS2) displayed an NDR at
the AR binding site. In addition, the AR collaborator GATA-2
was present at the NDR in androgen-deprived cells. Interest-
ingly, knockdown of GATA-2 resulted in loss of the NDR at
the TMPRSS2 enhancer but not at the KLK3 and KLK2 en-
hancers in the absence of hormone. These results suggest that
GATA-2 plays a role in maintaining NDRs in a locus-specific
manner. Treatment with androgen resulted in AR occupancy
and in increases in the number of enhancer modules displaying
NDRs at all three enhancers. The NDRs overlapped precisely
with the AR binding regions. We propose a model whereby,
in the absence of ligand, a single nucleosome at AR enhanc-
ers turns over more rapidly than surrounding ones, resulting
in a number of enhancer modules without the nucleosome at
any given time, while others are occupied by a nucleosome.
Under these conditions, pioneer factors such as GATA-2
play a role in maintaining this turnover equilibrium. We
further propose that upon androgen treatment and the re-
sulting AR occupancy, the turnover rates of nucleosomes
are altered to favor the nucleosome-depleted state, resulting
in an increased number of modules displaying NDRs at any
given time. This, in turn, may facilitate the recruitment of
histone modifiers to give rise to histone acetylation and
methylation at flanking nucleosomes, ultimately leading to
AR target gene expression.
MATERIALS AND METHODS
Cell culture. The prostate cancer cell line LNCaP and the IMR90 (human
fibroblasts) cell line were obtained from the American Type Culture Collection
(Manassas, VA). The prostate cancer cell line LAPC4 was a kind gift from
Charles Sawyers (UCLA, Los Angeles, CA). IMR90 cells (passages 4 to 7) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum (FBS). LNCaP cells (passages 25 to 46) were maintained in
phenol red-free RPMI 1640 containing 5% charcoal/dextran-stripped FBS
(Gemini, Woodland, CA) for 3 or 7 days prior to a 0.5-h, 2-h, 4-h, or 16-h
treatment with 10 nM 5--dihydrotestosterone (DHT; Sigma Chemical Co., St.
Louis, MO) or ethanol-treated control. LAPC4 cells were grown in phenol
red-free RPMI 1640 containing 5% charcoal/dextran-stripped FBS for 2 days
prior to a 4-h 10 nM DHT or ethanol treatment.
ChIP-Seq. LNCaP cells were treated for 4 h with 10 nM DHT after hormone
deprivation for 3 days. ChIP was carried out as previously described (20), using
antibodies against AcH3 and AR. Chromatin was fragmented to a size range of
200 to 400 bases with a Fisher Sonic Dismembrator. ChIP DNA was prepared
into libraries and sequenced using the Illumina Genome Analyzer II according to
the manufacturer’s protocols. We collected 15,963,583 (AR), 18,957,344 (AcH3),
and 17,079,409 (no antibody [Ab]) uniquely alignable 36-bp single end reads
from the Illumina Genome Analyzer IIx. Alignments were performed using
MAQ, and we used only reads with a unique mapping quality score of 30 or
greater. ChIP-Seq data tracks were generated by averaging read densities at
50-bp intervals (average reads per kbp). Because single-end sequencing was
used, we extended each tag by 250 bp in the appropriate direction. Peaks were
identified by examining average read counts in all such 500-bp windows and
selecting all with 15 or more reads within the window (30 reads per kbp). Based
on randomly distributed reads under the binomial distribution, windows with 15
or more reads are extremely unlikely to occur by chance (P values of 4.4E-11,
3.8E-10, and 8.3E-11 for AR, AcH3, and no Ab, respectively). Significant windows
were merged if they were within 100 bp of each other, yielding 4,762 highly
significant peaks for AR and 579 for the no-Ab control. A total of 405 AR peaks
overlapped no-Ab peaks and were removed, to yield 4,357 final AR peaks. The
fraction of AR peaks overlapped by an AcH3 peak (Fig. 1) was quantified by
aligning AcH3 peaks with the center of each AR peak.
ChIP analysis and ChIP-qPCR. LNCaP cells were maintained in phenol
red-free RPMI 1640 containing 5% charcoal/dextran-stripped FBS for 3 days
prior to 4 h of treatment with 10 nM DHT or an ethanol-treated control.
ChIP was carried out as described previously (20), using 4 g of antibodies
FIG. 1. Acetylated H3 flanks AR-occupied regulatory regions in LNCaP cells. (A) Genome-wide ChIP-Seq analysis shows 20% histone H3
enrichment surrounding AR-occupied regions (ARORs) in DHT-treated LNCaP cells. (B) ChIP-Seq profiles for recruitment of the AR and
histone H3 acetylated at Lys-9 and Lys-14 (AcH3) at the enhancers of three prototypical androgen-responsive genes (TMPRSS2, KLK2, and
KLK3). No-Ab and input controls are also shown. (C) qPCR analysis of TMPRSS2, KLK2, and KLK3 mRNA levels after 4 h (left panel) or 16 h
(right panel) of treatment with 10 nM DHT. Bars show expression relative to GAPDH levels (RQ) and represent the average of 3 independent
experiments  the SEM. *, P  0.05; **, P  0.01.
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targeting histone H3 (ab1791; Abcam, Cambridge, MA), acetylated histone
H3, Lys-9 and Lys-14 (06-599; Upstate Biotechnology Inc., Lake Placid, NY),
dimethyl histone H3, Lys-4 (07-030; Upstate Biotechnology Inc.), the AR
(N-20; Santa Cruz Biotechnology, Santa Cruz, CA), and GATA-2 (H-116;
Santa Cruz Biotechnology). ChIP DNA was quantified by real-time qPCR
using the Kapa SYBR Fast qPCR kit (Kapa, Woburn, MA) and the DNA
Engine Opticon System (Bio-Rad, Hercules, CA). The qPCR assays were
carried out using an arbitrary standard curve made from sonicated LNCaP
cells genomic DNA to enable direct comparison across different primer sets.
Data are represented as the average  the standard error of the mean (SEM)
from two independent experiments. All primers used for ChIP have a 60°C
annealing temperature and are detailed in Table 1. P values of differences in
the percentage of the input between primer sets 1 and 3 were calculated using
SAS (analysis of variance [ANOVA]) considering the two experiments and
PCR replicates as independent variables. P values of 0.05 are displayed in
Fig. 2.
RNA isolation and qPCR analysis of androgen-responsive genes and GATA-2.
Total RNA was extracted from DHT- or ethanol-treated control LNCaP or
LAPC4 cells at the indicated time points using TRIzol (Invitrogen, Carlsbad,
CA) and treated with DNase I (Invitrogen) according to the manufacturer’s
instructions. cDNA was prepared from 1 g RNA using Superscript III reverse
transcriptase (Invitrogen), and qPCR analysis for androgen-responsive genes
and GATA-2 was conducted using SYBR green KAPA master mix and primers
previously described (20, 22). Five microliters of sample was used for each qPCR.
The relative amount of transcript was calculated by the cycle threshold method
and normalized to the endogenous reference (glyceraldehyde 3-phosphate de-
hydrogenase [GAPDH]). The calibrator sample was randomly chosen from the
ethanol-treated cells. The relative amount of target gene expression for each
sample was calculated and plotted as the average  the SEM from two or three
independent experiments.
NOMe-Seq analysis of enhancers. Nucleosome occupancy and endogenous
methylation at enhancer regions were determined as previously described (31),
with minor modifications. Briefly, chromatin was isolated from 200,000 cells
treated for 4 h or 16 h with DHT or ethanol (LNCaP and LAPC4) or left
untreated (IMR90). Chromatin was incubated for 7.5 min with 200 U of enzyme
GpC methylase (M.CviPI; New England BioLabs), which methylates GpC sites,
followed by another 7.5 min of incubation with 100 U of M.CviPI. DNA was
extracted and bisulfite converted using the EPITEC Bisulfite kit (Qiagen, Va-
lencia, CA), and PCR fragments were cloned for sequencing of individual mol-
ecules.
PCR amplification of enhancer regions, cloning, and sequence analysis. The
sequences of the primer sets used to investigate the enhancer regions are shown
in Table 1. Enhancer regulatory regions were PCR amplified from bisulfite-
converted DNA and cloned using the TOPO TA cloning kit (Invitrogen). Col-
TABLE 1. ChIP and NOMe-Seq primer sets used in this study
Primer application and
name




































GRP78, R1 GAGAAGAAAAAGTTTAGATTTTATAG AAACACCCCAATAAATCAATC
a Enhancer/region.
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onies were screened for positive clones, and at least 15 positive clones per
amplicon were sequenced per experiment. Results shown represent two inde-
pendent biological replicates. Sequences were analyzed using the BiQ analyzer
software (4). Accessible regions (green bubbles) and inaccessible regions (white
bubbles, pink bar) were plotted as bubble charts. Statistical analysis (chi square)
of the ethanol and DHT treatments was performed for one GpC site every 100
bp. The percentage of inaccessible molecules was calculated for every GpC site
in the amplicon [percentage of inaccessibility  (number of inaccessible mole-
FIG. 2. Fine mapping of AR occupancy and histone modifications at the TMPRSS2, KLK2, and KLK3 enhancers using ChIP-qPCR. (A) Five regions
(black boxes 1 to 5) encompassing AR-occupied (green) and AcH3-modified (red) regions identified by ChIP-Seq were investigated by ChIP-qPCR
analysis. Also shown are the locations of the functional AR elements (AREs, green star) and predicted GATA-2 binding sites (blue rectangles).
(B) Site-specific ChIPs of AR, AcH3, H3K4me2, and H3 are presented as the average percentage of the input the SEM or as the average ratio to H3
the SEM of two independent experiments, in each case analyzed in duplicate or triplicate by qPCR. P values of percentages of the input between primer
sets 1 and 3 were calculated using SAS (ANOVA) considering the two experiments and PCR replicates as independent variables. *, P  0.05.
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cules/total number of molecules)  100], and the results were averaged over a
distance of 100 bp and plotted.
MNase digestion and qPCR analysis of enhancer regions. MNase digestion
was carried out as described by Gal-Yam et al. (12) without chromatin fraction-
ation. Cell lysates were incubated at 37°C for 15 min with increasing amounts of
MNase I to determine the amount of enzyme required to enrich for mononucleo-
somes. An MNase I level of 5 IU was found to be suitable (see Fig. 4A) and was
used in further experiments. LNCaP cells were maintained for 3 days in charcoal-
stripped serum (CSS) and treated with ethanol or 10 nM DHT for 4 h, followed
by MNase digestion. MNase-treated DNA was subjected to qPCR analysis using
SYBR green KAPA master mix. Untreated, sonicated DNA was used as a
control. Enhancer regions were investigated using 3 primer sets selected from
our ChIP analysis. Primers were located within the nucleosome-depleted region
(P3) and within the two flanking nucleosome-occupied regions (P2 and P5), as
determined by NOMe-Seq. The qPCR assays were carried out using standard
curves for each primer set made from sonicated LNCaP cells genomic DNA.
Results are presented as quantities relative to the most abundant amplicon for
each primer set (RQ). Results are shown as the averages of two independent
experiments.
GATA-2 knockdown. LnCaP cells were transfected with predesigned SMART-
pool small interfering RNA (siRNA) reagents against GATA-2 and nontargeted
(control) siRNA (Dharmacon, Lafayette, CO) as previously described, with
minor modifications. Briefly, 2  105 cells/well were plated in six-well plates and
grown in phenol red-free RPMI 1640 containing 5% CSS for 2 days. Cells were
transfected with the siRNA duplexes at a final concentration of 100 nM using
Oligofectamine reagent (Invitrogen) according to the manufacturer’s instruc-
tions. After transfection, cells were grown in phenol red-free RPMI 1640 con-
taining 5% CSS for 48 h and then treated with the ethanol vehicle for additional
4 h. Cells were harvested and processed for NOMe-Seq analyses. Total RNA and
protein extractions were also conducted to verify knockdown efficiency.
Western blot analysis. Immunoblotting was performed as previously described
(19, 24) using an antibody against GATA-2 (H116) from Santa Cruz Biotech-
nology, Santa Cruz, CA. Anti-histone H3 antibody (Abcam, San Francisco, CA)
was used as a loading control.
Data analysis. Statistical significance was determined by ANOVA, Student’s t
test or chi-square test as appropriate; P values of 0.05 were considered to be
significant.
RESULTS
ChIP-Seq analysis of DHT-treated LNCaP cells shows that
about 20% of all AR-occupied regions, including the
TMPRSS2, KLK2, and KLK3 enhancers, are flanked by AcH3
nucleosomes. Histone modifications surrounding transcription
factor binding sites (18, 21) and local nucleosome positioning
and displacement patterns provide information about the func-
tional states of chromatin (13, 17). In prostate cancer cells,
functionally significant chromatin signatures converge at AR-
occupied regions, since it is known that the AR drives the
disease (6). We aligned data obtained from a ChIP-Seq anal-
ysis of AR occupancy and histone AcH3 modification in
LNCaP cells treated for 4 h with the natural AR ligand DHT.
Figure 1A depicts 4,357 highly significant LNCaP cell AR-
occupied regions (gray) and the fraction of AR-occupied re-
gions overlapping a significant AcH3 peak at various distances
(blue). About 20% of the AR-occupied regions were associ-
ated with AcH3; remarkably, a 200- to 400-bp area surround-
ing the apex of the AR peak displayed a very low number of
AcH3 reads, possibly defining an NDR. In contrast, the flank-
ing regions had the highest number of AcH3 reads and showed
two well-defined peaks corresponding to two well-positioned
acetylated nucleosomes. This pattern is highly reminiscent of
that observed in other regulatory regions, such as promoters
(36) and CTCF binding sites (11), and the fact that it is present
in a large number of AR-occupied regions suggests that it may
play a role in the expression of target genes controlled by an
important group of enhancers.
We selected to study in detail the enhancers of three well-
established AR target genes, namely, TMPRSS2, KLK2, and
KLK3/PSA. The TMPRSS2 enhancer region is located approx-
imately 13.5 kb upstream of the transcriptional start site and
contains a noncanonical AR binding site. ChIP-Seq of AcH3
and AR occupancy in DHT-treated LNCaP cells showed two
clear AcH3 peaks, flanking the AR binding site (arrow) at the
TMPRSS2 enhancer (Fig. 1B). Other androgen-occupied re-
gions at this locus were not studied further. The KLK3 en-
hancer is located between 5.8 and 3.7 kb upstream of the
transcriptional start site, and the KLK2 enhancer spans the
region situated between 4.4 and 3.8 kb from the transcriptional
start site (27). As previously reported (3), and similar to the
TMPRSS2 enhancer, two clear AcH3 peaks were found to
flank the AR binding site at the KLK2 and KLK3 enhancers
(Fig. 1B). These results suggest that, at the enhancers of an-
drogen-responsive genes, AR is bound to an NDR which is
flanked by two well-positioned nucleosomes containing AcH3.
From these results, however, it is unclear whether the AcH3-
free region may contain native unmodified histones or whether
the proposed NDR precedes or follows AR binding.
AR recruitment leads to enrichment of AcH3 and H3K4me2
at the TMPRSS2, KLK2, and KLK3 enhancers. To validate our
ChIP-Seq observations, we analyzed gene expression, histone
acetylation and methylation, and AR occupancy at the chosen
three AR enhancer loci. As expected, 4 h of treatment with
DHT significantly increased the TMPRSS2, KLK2, and KLK3
mRNA levels in LNCaP cells compared to those in hormone-
deprived cells (Fig. 1C, left panel). Further increases were
observed after 16 h of treatment for all three genes (Fig. 1C,
right panel).
Site-specific ChIP-qPCR analyses of AR occupancy, AcH3,
H3K4me2 modifications, and native histone H3 were con-
ducted at the TMPRSS2, KLK2, and KLK3 enhancers. Five
primer sets (Table 1) were used to map the AR-occupied
regions and AcH3 peaks at the enhancers. Figure 2A displays
a detailed image of the ChIP-Seq AcH3 (black ticks) and AR
(green ticks) signals in LNCaP cells treated for 4 h with DHT
and the relative positions of the five ChIP primer sets (P1 to
P5) for each locus. ChIP analysis of AR occupancy (Fig. 2B) in
DHT-treated LNCaP cells (green) shows a pattern similar to
that observed in our ChIP-Seq data for all three enhancer
regions. Significantly higher (P  0.05) AR occupancy (green
bars) was detected in the regions mapped by primer set P3 for
at all three loci, than in the regions mapped by primer set P1
(located at the edge of enhancers). In contrast, negligible to no
AR occupancy was observed in hormone-deprived cells (Fig. 2,
red bars), indicating that AR binds to these loci only in the
presence of DHT, a phenotype well known for androgen-de-
pendent LNCaP cells. In agreement with the ChIP-Seq find-
ings, AcH3 increased at the enhancers after DHT treatment
(green bars) in a bimodal fashion, with two acetylation peaks
in the regions mapped by primer sets P1, P4, and P5 for
TMPRSS2 and by primer sets P1, P2, and P5 for KLK2 and
KLK3 (Fig. 2). AcH3 enrichment was significantly higher (P 
0.05) in the region mapped by primer set P1 (located at the AR
binding site) than in the region mapped by primer set P3 for all
three enhancers. Also in agreement with the ChIP-Seq analy-
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sis, we found that the area corresponding to AR binding con-
tained lower levels of AcH3. Hormone-deprived cells dis-
played very low acetylation across the five primer sets (red
bars). Similarly, H3K4me2 was enriched in a bimodal pattern
only in DHT-treated samples. H3K4me2 enrichment was sig-
nificantly higher (P 0.05) in the region mapped by primer set
P1 than in the region mapped by primer set P3 for the
TMPRSS2 and KLK2 enhancers. Finally, H3 was detected at
higher levels in hormone-deprived samples at all three enhanc-
ers than in DHT-treated ones. The KLK2 enhancer showed a
clear bimodal pattern of distribution of H3 in the androgen-
deprived samples. Significant differences were found between
primer set P1 and primer set P3, suggesting the presence of an
NDR in the hormone-deprived sample. Such a pattern was not
readily apparent for the TMPRSS2 and KLK3 enhancers, al-
though significant differences in H3 enrichment were found
between primer set P1 and primer set P3 at the KLK3 en-
hancer. When corrected for H3 levels (Fig. 2B, bottom panels),
AcH3 levels were the same across all regions in the absence of
DHT for all the enhancers; upon hormone treatment, AcH3
enrichment was observed in the regions flanking the AR bind-
ing site. In contrast, the levels of H3K4me2 corrected for H3
levels in the absence or presence of hormone at all enhancers
were different than those shown when data were presented as
percentages of the input, indicating that the observed deple-
tion of H3K4me2 (when presented as a percentage of the
input) simply reflected the presence of histones at the sites.
The dramatic increase in AcH3 and H3K4me2 at all sites after
DHT treatment more clearly demonstrated that the modifica-
tions occurred as a consequence of DHT treatment.
A percentage of TMPRSS2, KLK2, and KLK3 enhancer mod-
ules displays NDRs in the absence of ligand. The results from
the KLK2 and KLK3 enhancers were intriguing, particularly
since it has recently been proposed that nucleosomes occupy
AR enhancer regions in the absence of DHT (14). A possible
explanation for the differences we observed between enhancers
in terms of nucleosome positioning as determined by H3 ChIP
analysis is the limited resolution level of the assay. To better
resolve the pattern of nucleosome positioning and displace-
ment in response to hormone treatment, we performed a high-
resolution, single-molecule analysis named NOMe-Seq. This
method is based on DNA accessibility to the 40,000-Da
M.CviPI molecule, which methylates cytosines at GpC dinucle-
otides, and has been successfully used to establish nucleosome
positions at promoters regions (23, 45). The advantage of
NOMe-Seq analysis over traditional assays is that it allows the
investigation of nucleosome position and endogenous methyl-
ation in the same molecule in CpG-poor regions (23) such as
enhancers and without the biases previously reported for
MNase I (2, 8). In addition, NOMe-Seq provides a digital
readout of nucleosome positioning, thereby allowing direct
comparison between treatments. Because NOMe-Seq relies on
GC density, loss of resolution may be observed in extremely
GC-poor regions. However, the three AR enhancers analyzed
in this study have reasonably good GC densities, as do the
majority of the gene-rich regions of the genome (28, 42), and
therefore optimal resolution for the NOMe-Seq assay was ex-
pected. We designed two overlapping sets of primers (Table 1)
lacking both GpC and CpG sites to eliminate amplification
biases, which covered the full enhancer and additional neigh-
boring regions of TMPRSS2, KLK2, and KLK3/PSA (Fig. 3A).
Primer location was based both on the coordinates of previ-
ously characterized enhancers (32, 37, 43, 47) and on the lo-
cations of AR-enriched peaks as determined in our genome-
wide ChIP-Seq data (Fig. 1A). The results represent two
independent experiments per time point and show a clear
M.CviPI-accessible region (teal) in the hormone-deprived
sample for all three enhancers (Fig. 3A). However, the degree
of accessibility to M.CviPI differed among the regions, with the
KLK2 enhancer being the most accessible (41% of enhancer
modules being nucleosome depleted), the TMPRSS2 enhancer
moderately accessible (26%), and the KLK3 enhancer the least
accessible (14%) (Fig. 3A and B). The observed accessible
regions were large enough to accommodate at least one
nucleosome, showing that even in the absence of androgens,
some enhancer modules have NDRs. After 4 h of treatment
with DHT (Fig. 3A and B), a significant increase in the number
of accessible modules was observed at all three enhancers.
Interestingly, the size (footprint) of the NDRs was not appre-
ciably altered. The increase in numbers relative to the control
sample was also differential and mirrored the pattern observed
for the hormone-deprived samples as follows: TMPRSS2, 34%;
KLK2, 27.2%; KLK3, 17.5% (Fig. 3B). In addition, M.CviPI
accessibility in both hormone-deprived and DHT-treated sam-
ples was observed after 16 h in culture for all three enhancers
(Fig. 3C).
To confirm nucleosome depletion at the AR binding site in
the absence of hormone, we carried out MNase digestion fol-
lowed by qPCR analysis of the TMPRSS2 and KLK2 enhancers
in LNCaP cells as previously reported (12, 30). We selected
three primer sets (P2, P3, and P5) from the five used for our
ChIP analyses (Fig. 2), which covered the nucleosome-de-
pleted (P3) enhancer region and two nucleosome-occupied
(P2, P5) enhancer regions, as previously established by NOMe-
Seq (Fig. 3). We first determined that the amount of MNase
enzyme suitable to enrich for mononucleosomes was 5 IU (Fig.
4A). MNase digestion of LNCaP cells treated with DHT or
ethanol for 4 h (after exposure to CSS for 3 days) clearly show
a decrease in amplified product in the ethanol-treated samples
at both enhancer regions (Fig. 4B). However, MNase digestion
was less sensitive than NOMe-Seq in detecting changes in
nucleosome depletion as a result of DHT treatment. The P3
primer set used in this analysis was located within the NDR
detected by NOMe-Seq, which, according to its size, can ac-
commodate only one nucleosome. Therefore, the decrease in
amplified product is likely to reflect true nucleosome deple-
tion, in agreement with the NOMe-Seq results.
In the absence of ligand, a percentage of TMPRSS2 and
KLK2 enhancer modules always shows NDRs and this percent-
age increases after short-term treatment with DHT. To eval-
uate the kinetics of nucleosome positioning at AR enhancers,
we performed NOMe-Seq analysis after short-term exposure
to DHT (Fig. 5). A small increase in TMPRSS2 and KLK2
expression was observed as early as 0.5 h after DHT treatment
(Fig. 5A). Results from the NOMe-Seq analysis of TMPRSS2
and KLK2 enhancers (Fig. 5B to E) clearly show 39 to 50%
accessibility to M.CviPI (teal) in the ethanol-treated control
samples, independently of the time of exposure to ethanol (0.5
h or 2 h). Treatment with DHT induced a significant increase
in the number of accessible enhancer modules as early as 0.5 h
VOL. 31, 2011 NUCLEOSOME DEPLETION AT UNOCCUPIED AR ENHANCERS 4653
 o
n








FIG. 3. Nucleosome positioning in TMPRSS2, KLK2, and KLK3 enhancers as determined by NOMe-Seq analysis. (A) Single-molecule analysis
of nucleosome occupancy for TMPRSS2, KLK2, and KLK3 enhancers. Maps show GpC site density and the location of the enhancer (green bar)
in the regions analyzed. DNA modules showing methylase-accessible regions (teal bubbles, upper panel) were present in the ethanol-treated
control in all three enhancers. After DHT treatment, more DNA modules showed increased accessibility (teal bubbles, bottom panel). A chi-square
test was carried out for seven GpC sites, chosen every 100 bp and indicated by arrows (a to g) on the enhancer map. Significant differences in
nucleosome depletion between ethanol- and DHT-treated samples were found for the TMPRSS2 enhancer (c, P  0.0012), the KLK2 enhancer
(d, P  0.03; e, P  0.00009; f, P  0.014; g, P  0.009), and the KLK3/PSA enhancer (d, P  0.004). (B) Percentage of inaccessible GpC sites
after 4 h of DHT treatment. The average percentage of inaccessible GpC sites every 100 bp is shown. The ethanol-treated control sample (red
curve) showed a variable range of accessibility across the enhancer regions analyzed. Treatment with DHT (green curve) broadened the range; the
percent increase in accessibility between ethanol- and DHT-treated samples is shown. The position of the enhancer (green bar under the graph)
and the locations of the primer sets (P1 to P5) used in the ChIP-qPCR analysis are also shown. Note that the peak of accessibility overlaps the
AR binding region mapped by ChIP-qPCR analysis. (C) Percentage of inaccessible GpC sites after 16 h of DHT treatment. A similar pattern of
accessibility was observed after 16 h of treatment with DHT.
4654 ANDREU-VIEYRA ET AL. MOL. CELL. BIOL.
 o
n








posttreatment without affecting the size (footprint) of the
NDRs, as was observed at later time points. The maximum
increase in the number of accessible enhancer modules at the
TMPRSS2 enhancer (61%) was observed 0.5 h after exposure
to DHT (Fig. 5B and C). At the KLK2 enhancer, this value
increased to17.5% after 0.5 h of DHT exposure (Fig. 5B and
4C) and 21.7% after 2 h of exposure to DHT (Fig. 4D and E),
which was similar to that observed after 4 h of treatment.
These results suggest that nucleosome depletion in response to
DHT treatment occurs shortly after DHT stimulation and co-
incides with AR occupancy.
NDRs are present after long-term androgen withdrawal.
The NDR detected in the hormone-deprived sample could be
caused by a transient short memory of the AR presence due to
recent exposure (3 days) of LNCaP cells to androgens. To
evaluate this possibility, we cultured cells in CSS for 7 days
(i.e., longer time of hormone deprivation) prior to the 4-h
treatment with DHT (Fig. 6). Our results indicate that even
after prolonged hormone deprivation, the NDR is maintained
at some of the TMPRSS2 enhancer modules in the hormone-
deprived sample (Fig. 6A and B), making it unlikely that the
NDR is caused by a transient memory of the prior AR pres-
ence. In addition, prolonged hormone deprivation did not af-
fect the response to DHT (Fig. 6A and B) and an 18% increase
in accessibility relative to that in the hormone-deprived sample
was observed.
Nucleosome positioning analyses of LAPC4 and IMR90
cells. To determine whether the patterns of nucleosome posi-
FIG. 4. MNase I analysis of the TMPRSS2 and KLK2 enhancers after 4 h of DHT treatment. (A) Representative depiction of MNase-digested
samples. LNCaP cells were treated with ethanol or DHT for 4 h after the cultures had been exposed to CSS for 3 days; cells were lysed and
chromatin was digested using 0.5 or 5 IU of MNase I for 15 min. Note that there is enrichment for mononucleosomes (arrow, 150 bp) after
treatment with 5 IU MNase and this amount was selected for further studies. (B) MNase-treated DNA was subjected to qPCR analysis using 3
sets of primers selected from our ChIP analysis (P2, P3, and P5). Primers cover the nucleosome-depleted region (P3) and two nucleosome-occupied
regions (P2 and P5) as determined by NOMe-Seq. The positions of the primer sets are indicated on the enhancer (green bar) maps. Note that
nucleosome depletion (seen as a dip in the graphs) was observed in the ethanol-treated control sample, in agreement with the NOMe-Seq results.
A small increase in nucleosome depletion was observed in the region mapped by P3 after DHT treatment. The average results from two
independent experiments are shown.
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FIG. 5. NOMe-Seq analysis of nucleosome occupancy for TMPRSS2 and KLK2 enhancers after short-term DHT treatment. All cultures were
exposed to CSS for 3 days prior to the start of the experiments. (A) qPCR analysis of TMPRSS2 and KLK2 mRNA levels after 0.5 h, 2 h, and 4 h
of treatment with 10 nM DHT. Expression levels (RQ) are relative to GAPDH levels (n  2). (B and D) Nucleosome positioning in LNCaP cells
after 0.5 h (B) and 2 h (D) of treatment with DHT. Enhancer maps show GpC site density and the location of the enhancer (green bar) in the
regions analyzed. DNA modules showing M.CviPI-accessible regions (teal bubbles) were present in the ethanol-treated control at both enhancers
(upper panels). More modules became accessible to the methylase after DHT treatment (teal bubbles, bottom panels). Four GpC sites, chosen
every 100 bp and indicated by arrows (a to d) on the enhancer map, were subjected to statistical analysis using the chi-square test. A significant
difference in nucleosome depletion between ethanol- and DHT-treated samples was found for the TMPRSS2 enhancer at position b (P  0.004)
and for the KLK2 enhancer at position a (P  0.016) after 0.5 h of treatment. No statistically significant difference was observed for the KLK2
enhancer after 2 h of treatment with DHT. (C and E) Percentages of inaccessible GpC sites in LNCaP cells after 0.5 h (C) and 2 h (D) of treatment
with DHT. The average percentage of inaccessible GpC sites every 100 bp is shown. Note that the ethanol-treated control sample (red curve)
showed a variable range of accessibility across the enhancer regions analyzed. Treatment with DHT (green curve) broadened the range; the percent












tioning were conserved among androgen-sensitive cell lines, we
performed a NOMe-Seq analysis with LAPC4 cells, which ex-
press the wild-type AR (Fig. 7). Cells were treated with DHT
or ethanol for 4 h after exposure to CSS for 2 days. The pattern
of nucleosome occupancy for the KLK2 enhancer (Fig. 7A and
B) was comparable to that of LNCaP cells (Fig. 3A). Impor-
tantly, 75% of KLK2 enhancer modules had NDRs in the
ethanol-treated control samples. In contrast, the TMPRSS2
enhancer was occupied by nucleosomes (pink bars) in the eth-
anol-treated sample (Fig. 7A and B), suggesting that accessi-
bility of the enhancers in the absence of ligand may vary among
androgen-responsive cell lines. DHT treatment increased the
number of enhancer modules displaying NDRs without affect-
ing the footprint size, as was also shown for LNCaP cells. The
increase in enhancer accessibility in response to DHT was
accompanied by increases in gene expression (Fig. 7C). The
same enhancer regions in the human fibroblast cell line
IMR90, which expresses neither TMPRSS2 nor KLK2 (Onco-
mine; Compendia Bioscience, Ann Arbor, MI), showed com-
plete nucleosome occupancy (Fig. 7D). On the other hand, the
GRP78/HSPA5 promoter, which is expressed in these cells
(Oncomine; Compendia Bioscience, Ann Arbor, MI), showed
a pattern of M.CviPI accessibility typical of active promoters
(Fig. 7D), as was previously reported by our group (12). The
three enhancer regions were CpG poor and, as expected,
showed very low endogenous methylation levels within the
enhancer in both LNCaP and LAPC4 cells (data not shown).
The TMPRSS2, KLK2, and KLK3 enhancers show GATA-2
enrichment in the absence of ligand. The AR, acting in concert
with other (pioneer) transcription factors such as GATA-2,
OCT-1, and FOXA1, mediates the expression of androgen-
responsive genes. In particular, OCT1 and GATA-2 have been
shown to regulate TMPRSS2 and KLK3 expression (33, 43),
and GATA-2 has also been shown to regulate KLK2 expression
(5). FOXA1 and GATA-2 act as pioneer factors in the recruit-
ment of AR, although FOXA1 appears to be recruited to a
restricted number of sites (43). In yeast, the transcription fac-
tor RSC3 was shown to be required for the maintenance of an
NDR in the proximal promoter region of a number of genes
that contain the RSC3 binding motif (1). However, a similar
role for transcription factors at promoters or in other regula-
tory regions has not been described in mammals.
Since pioneer factors are present at AR enhancers in the ab-
sence of DHT, we hypothesized that their binding affects the
turnover rates of nucleosomes in these regions toward the
nucleosome-depleted state, as previously suggested (29). To
test this hypothesis, we used ChIP-qPCR to verify GATA-2
binding to the TMPRSS2, KLK2, and KLK3 enhancers by
ChIP. The results show that GATA-2 is enriched in all three
enhancers irrespective of the presence of DHT (Fig. 8A),
which is consistent with the presence of GATA response ele-
ments at all three loci (blue rectangles, Fig. 2A). Furthermore,
we found that GATA-2 was particularly enriched at the NDRs.
For instance, comparing the results of the GATA-2 ChIP anal-
ysis and nucleosome positioning at the KLK2 enhancer makes
it clear that the regions amplified by P3 and P4 show both the
highest signal for GATA-2 binding (Fig. 8A, middle panel) and
an NDR (Fig. 3B).
GATA-2 is important for NDR maintenance at the
TPMRSS2 enhancer in the absence of hormone. Next, using
FIG. 6. Nucleosome positioning in the TMPRSS2 enhancer as de-
termined by NOMe-Seq analysis after extended androgen deprivation.
LNCaP cells were cultured in CSS for 7 days and then treated with
ethanol (control) or DHT (10 nM) for 4 h. (A) Single-molecule anal-
ysis of nucleosome occupancy for the TMPRSS2 enhancers. Enhancer
maps show GpC site density and the location of the enhancer (green
bar) in the region analyzed. DNA modules showing M.CviPI-accessible
regions (teal bubbles, upper panel) were present in the ethanol-treated
control, and after DHT treatment, more DNA modules showed in-
creased accessibility (teal bubbles, bottom panel). Seven GpC sites,
chosen every 100 bp and indicated by arrows (a to g) in the enhancer
map, were subjected to statistical analysis using the chi-square test. A
significant difference in nucleosome depletion between ethanol- and
DHT-treated samples was found for the TMPRSS2 enhancer at posi-
tion d (P  0.047). (B) Percentage of inaccessible GpC sites after 4 h
of DHT treatment. The average percentage of inaccessible GpC sites
every 100 bp is shown. Note that the ethanol-treated control sample
(red curve) also showed accessibility after extended androgen depri-
vation. Treatment with 10 nM DHT (green curve) broadened the
range; the percent increase in accessibility between ethanol- and DHT-
treated samples is apparent. The position of the enhancer relative to
the accessibility region is shown as a green bar under the graph. The
locations of the primer sets (P1 to P5, Fig. 2) used in the ChIP-qPCR
analysis are also shown. Note that the peak of accessibility overlaps the
AR binding region mapped by ChIP-qPCR analysis.
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FIG. 7. NOMe-Seq analysis of nucleosome occupancy for TMPRSS2 and KLK2 enhancers in LAPC4 and IMR90 cells. Enhancer maps show
GpC site density and the locations of the enhancers (green bar) in the regions analyzed. (A) LAPC4 cells were maintained in CSS for 2 days and
treated with ethanol (control) or DHT for 4 h. DNA modules showing that M.CviPI-accessible regions (teal bubbles, upper panel) were present
in the ethanol-treated control at the KLK2 and TMPRSS2 enhancers in LAPC4 cells (upper panel). Similar to LNCaP cells, increased DNA
accessibility to the methylase was observed in both enhancers after 4 h of treatment with DHT (teal bubbles, bottom panel). Four (TMPRSS2) or
five (KLK2) GpC sites, chosen every 100 bp and indicated by arrows (a to d, a to e) on the enhancer map, were subjected to statistical analysis
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siRNA to knock down the levels of endogenous GATA-2 in
LnCaP cells, we investigated the role of this pioneering factor
in maintaining the NDRs at AR enhancers in the absence of
hormone. A 70% decrease in GATA-2 mRNA levels (Fig. 8,
top panel) and a further decrease in protein levels (Fig. 8B,
bottom panel) were observed in LnCaP cells after GATA-2
knockdown. Analysis of nucleosome positioning by NOMe-Seq
revealed that knockdown of GATA-2 significantly (P  0.05)
decreased the accessibility of the TMPRSS2 enhancer to
M.CviPI by 44% but did not alter the accessibility of the KLK2
and KLK3 enhancers (Fig. 8C and D). However, after GATA-2
knockdown, a new accessible area was observed downstream of
the KLK3 enhancer. This area is smaller than a nucleosome
and may reflect transcription factor loss (either GATA-2 or
others). The results suggest a “pioneering” role for GATA-2 at
some, but not all, AR enhancers and provide support for the
hypothesis that pioneer factors help maintain enhancer acces-
sibility for subsequent transcription factor binding and action.
DISCUSSION
Nucleosome positioning at promoter regions is being in-
creasingly recognized as an important factor in the regulation
of gene expression (34), and nucleosome turnover kinetics,
“sliding,” and “hopping” have been proposed to facilitate such
regulation (29, 35). Nucleosomes affect the way transcription
factors bind to their recognition sequences, thereby modulat-
ing transcription (2). Whereas some transcription factors may
require NDRs for binding, others may bind with low affinity
even if a nucleosome is present or bind with high affinity
irrespective the presence or absence of a nucleosome. Binding
of transcription factors to an NDR may confer the advantage
of a quick response and allow low transcription factor titers to
remain functional (2).
Here, using a combination of ChIP and a high-resolution,
single-molecule nucleosome positioning assay, we show that, in
LnCaP cells and in the absence of the AR ligand/hormone
(DHT), the enhancers of androgen-responsive genes have
NDRs whose locations overlap those of GATA-2-enriched re-
gions. A similar pattern of nucleosome occupancy was found in
another prostate cancer cell line, LAPC4, but not in human
fibroblasts, suggesting that this might be a conserved feature of
AR enhancers in androgen-sensitive cells. Treatment with
DHT induces AR recruitment and increases the number of
DNA enhancer modules displaying NDRs but not the size of
the nucleosome-depleted area. Based on our results, we pro-
pose a model by which AR enhancers exist in an equilibrium in
which the turnover rates of nucleosomes create a population of
enhancer modules with a clear NDR at any given time. DHT
treatment, which recruits the AR to the sites, changes the
equilibrium toward the nucleosome-depleted state, and as a
consequence, more enhancer modules display NDRs. The in-
crease in the number of modules showing NDRs was observed
even at 0.5 h after DHT exposure, suggesting that the shift of
the equilibrium toward a more nucleosome-depleted state is
very rapid. The exact mechanism by which the NDRs are
established and maintained in the absence of DHT is un-
known. One possibility is that the NDRs are passively formed
as a consequence of spontaneous DNA accessibility and main-
tained by the binding of transcription factors (29). Our data
showing GATA-2 binding in the absence of DHT, as well as
the disappearance of the NDR after GATA-2 knockdown, at
some but not all AR enhancers support this hypothesis. We
propose that other factors may be required to displace the
equilibrium toward a more nucleosome-depleted configuration
after DHT treatment, a hypothesis that is in line with the
model of factor cooperativity reviewed by Segal and Widom
(38).
A recent study by He et al. (14) described a nucleosome-
occupied region in the area corresponding to the AR binding
site at the enhancers of androgen-responsive genes under hor-
mone-deprived conditions, based on prediction algorithms
built on MNase I digestion and ChIP-Seq data. Those authors
also indicated that nucleosomes in that region contain the
histone variant H2A.Z, which they suggested may destabilize
those nucleosomes. However, the stability of the nucleosome
was not tested. Although we did not analyze H2A.Z enrich-
ment at the three well-characterized AR enhancers studied
here, our analysis of nucleosome occupancy using NOMe-Seq
clearly shows that NDRs do, in fact, exist in the absence of
hormone. MNase analysis of LNCaP cells treated with ethanol
or DHT for 4 h confirmed an NDR in ethanol-treated samples,
in agreement with our NOMe-Seq results. Since we found that
a given percentage of enhancer modules was inaccessible in
both the presence and the absence of DHT, our data are
consistent with the hypothesis that nucleosomes positioned at
the center of the AR binding site may be more labile, perhaps
as a consequence of carrying the H2A.Z histone variant, as
proposed by He et al. (14). Our finding that more modules
displayed NDRs after DHT treatment is entirely consistent
with that of He et al. (14).
Our H3K4me2 ChIP data analysis is also in agreement with
that reported by He et al. (14), who showed that two well-
positioned nucleosomes containing this histone modification
flank the AR binding site after DHT stimulation. However,
both our native H3 and H3K4me2 ChIPs suggest that there is
using the chi-square test. A significant difference in nucleosome depletion between ethanol- and DHT-treated samples was found in the TMPRSS2
enhancer at positions b (P  0.03) and c (P  0.0115); no significant differences between treatments were found for the KLK2 enhancer. (B)
Percentage of inaccessible GpC sites after 4 h of DHT treatment. The average percentage of inaccessible GpC sites every 100 bp is shown. Note
that the ethanol-treated control sample (red curve) also showed accessibility after extended androgen deprivation. Treatment with 10 nM DHT
(green curve) broadened the range; the percent increase in accessibility between ethanol- and DHT-treated samples is shown. The position of the
enhancer relative to the accessibility region is shown as a green bar under the graph. (C) qPCR analysis of TMPRSS2 and KLK2 mRNA levels after
4 h of treatment of LAPC4 cells with 10 nM DHT. Expression is shown relative to GAPDH levels (RQ, n  2). (D) IMR90 cells, which do not
express TMPRSS2 or KLK2, showed total inaccessibility to M.CviPI for both of the enhancers. In contrast, and as expected, the promoter region
of the expressed gene HSPA5/GRP78 (70-kDa heat shock protein 5/78-kDa glucose-regulated protein) was readily accessible to M.CviPI (teal
bubbles).
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FIG. 8. GATA-2 occupancy at the TMPRSS2, KLK2, and KLK3 enhancers and nucleosome positioning in LNCaP cells after GATA-2
knockdown. (A) GATA-2 occupancy was detected at all three enhancers in both ethanol-treated control cells (red solid bars) and DHT-treated
cells (green solid bars), as shown by enrichment of immunoprecipitated DNA compared with the respective no-antibody controls (red and green
open bars). Site-specific ChIPs (see Fig. 2) of GATA-2 are presented as the average percentage of the input  the SEM of two independent
experiments, in each case analyzed in duplicate or triplicate by qPCR. LNCaP cells were transfected with siRNA against GATA-2 or nontargeted
siRNA (control); cells were maintained in CSS for 2 days and treated with ethanol for 4 h. (B) qPCR (upper panel) and Western blot (lower panel)
analyses of GATA-2 mRNA and protein levels after GATA-2 knockdown. Mock-transfected cells and cells transfected with nontargeted (Ntg)
siRNA were used as controls. Expression is shown relative to GAPDH levels (RQ, n  2). A representative blot is shown. Histone H3 was used
as a loading control. (C) Enhancer maps showing GpC site densities and the locations of the enhancers (green bar) in the regions analyzed. DNA
modules showing M.CviPI-accessible regions (teal bubbles) were present in the nontargeted control at all enhancers. Note that accessibility after
GATA-2 knockdown was reduced only at the TMPRSS2 enhancer. A chi-square test was carried out for the TMPRSS2 enhancer at four GpC sites,
chosen every 100 bp and indicated by arrows (a to d) on the enhancer map. Significant differences in nucleosome depletion between nontargeted
control and GATA-2 siRNA-treated samples were found for the TMPRSS2 enhancer (a and b, P  0.05). (D) Percentage of inaccessible GpC sites
after GATA-2 knockdown. The average percentage of inaccessible GpC sites every 100 bp is shown. Note that a 44% decrease in M.CviPI
accessibility was observed for the TMPRSS2 enhancer.
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no enrichment of these marks at the central AR binding re-
gions relative to the flanking sites in cells maintained in the
absence of DHT, in agreement with the NOMe-Seq data re-
ported in this report. The presence of NDRs at other AR
enhancers in the absence of hormone remains to be elucidated;
however, our results provide support for the hypothesis that a
percentage of AR enhancer modules at a particular locus is
primed to accept the transcription factor, even under hormone
ablation conditions like those that exist in the course of treat-
ment of advanced prostate cancer cases.
AR signaling is critical in all phases of prostate cancer,
including disease initiation, androgen-dependent tumor
growth, and the evolution of resistance to androgen ablation
therapies (26). The mechanisms proposed to contribute to
ablation-resistant growth of prostate cancer all involve reacti-
vation of the AR under ablation conditions (reviewed in ref-
erence 46). A major mechanistic advance has been the real-
ization that the ablation-resistant phenotype in many tumors is
accompanied by the fusion of TMPRSS2 (along with its AR
enhancer) and ETS transcription factor genes, allowing AR
stimulation of the powerful secondary transcription factor fam-
ily (46) or by the expression of AR constitutively active splicing
variants (40). Furthermore, the involvement of the AR in the
ablation-resistant phenotype was clearly demonstrated by the
disruption of AR expression, which inhibited the proliferation
of ablation-resistant prostate cancer cells in the absence of
androgens (48). AR expression was also shown to be necessary
and sufficient to convert androgen-sensitive prostate cancer to
an ablation-resistant state (7). These lines of evidence prove
that aberrant AR signaling and its target genes are sufficient to
cause prostate cancer and that under certain conditions the
AR gene may be considered an oncogene.
The role of AR enhancers in prostate cancer represents the
other side of the same coin. Enhancers activate gene expres-
sion independently of their orientation and are commonly scat-
tered across large noncoding intervals, as well as within in-
trons. It is also important to note that enhancers are often cell
type specific (15), and in the case of prostate cancer, AR
enhancers drive all phases of the disease, as discussed above.
Work described in this report adds to the growing body of
evidence demonstrating the pivotal role of the AR and its
enhancers in the development of the ablation-resistant pheno-
type in prostate cancer. Our data showing that AR enhancers
seem to be “primed” for or “receptive” to AR activity during
hormone-depleted conditions underscore a possible mecha-
nism by which they may become efficiently engaged by AR
during the course of hormone ablation treatment of prostate
cancer patients. Furthermore, our study points to AR enhanc-
ers as critical genomic regions with therapeutic potential to
treat ablation-resistant prostate cancer.
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